ArticleJournal of pharmaceutical health care and sciences2025
Association between antibody-dependent cellular cytotoxicity activity of antitumor antibodies and infusion reactions: a pharmacovigilance analysis using the Japanese adverse drug event report database.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences.The international journal of neuropsychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfusion reactions (IRs) are common adverse events associated with biologics, often triggered by cytokine release from immune and tumor cells. Antibody-dependent cellular cytotoxicity (ADCC) is a key immune mechanism in which therapeutic antibodies recruit immune effector cells, such as natural killer cells, to induce target cell lysis. This study aimed to clarify the association between activated ADCC and IRs in antitumor antibodies using the Japanese Adverse Drug Event Report (JADER) database.
methodsData from the JADER database (April 2004 to February 2022) were analyzed to identify IRs related to 25 antitumor antibodies. The reporting odds ratio (ROR) was calculated to assess the association between IRs and antitumor antibodies, and statistical analyses were conducted using Fisher's exact test.
resultsAvelumab was the only anti-PD-1/PD-L1 antibody with a significant association with IRs (ROR: 5.44, 95% confidence interval [CI]: 3.59-8.22). Antibodies with ADCC activity detected significantly more IR signals (9/14, 64.3%) than those without ADCC activity (1/11, 9.1%; p = 0.0119).
conclusionsThis study suggests an association between ADCC and the occurrence of IRs in antitumor antibodies based on JADER database analysis. These findings provide valuable insights for the prevention and management of IRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.